Research programme: anaplastic lymphoma kinase inhibitors - Novartis

Drug Profile

Research programme: anaplastic lymphoma kinase inhibitors - Novartis

Alternative Names: NPM-ALK inhibitor; NVP-TAE684; TAE 684

Latest Information Update: 20 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Novartis; Scripps Institutions of Medicine and Science
  • Class Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Lymphoma

Most Recent Events

  • 19 Jul 2007 Preclinical trials in Lymphoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top